Ameriprise Financial Inc. increased its position in Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) by 17.3% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 912,740 shares of the specialty pharmaceutical company’s stock after buying an additional 134,544 shares during the period. Ameriprise Financial Inc. owned 1.85% of Supernus Pharmaceuticals worth $18,592,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. A.R.T. Advisors LLC acquired a new stake in Supernus Pharmaceuticals during the first quarter worth approximately $590,000. Springbok Capital Management LLC raised its stake in shares of Supernus Pharmaceuticals by 88.0% in the first quarter. Springbok Capital Management LLC now owns 19,927 shares of the specialty pharmaceutical company’s stock worth $304,000 after buying an additional 9,327 shares in the last quarter. Granahan Investment Management Inc. MA purchased a new stake in shares of Supernus Pharmaceuticals during the first quarter worth about $5,945,000. Nicholas Investment Partners LP purchased a new stake in shares of Supernus Pharmaceuticals during the first quarter worth about $1,990,000. Finally, Neumeier Poma Investment Counsel LLC raised its stake in shares of Supernus Pharmaceuticals by 33.6% in the first quarter. Neumeier Poma Investment Counsel LLC now owns 1,203,930 shares of the specialty pharmaceutical company’s stock worth $18,360,000 after buying an additional 302,600 shares in the last quarter. Hedge funds and other institutional investors own 94.66% of the company’s stock.

Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) traded up 2.25% on Tuesday, hitting $25.47. The company’s stock had a trading volume of 529,491 shares. The firm has a 50 day moving average of $22.55 and a 200-day moving average of $19.08. The stock has a market cap of $1.26 billion, a PE ratio of 51.98 and a beta of 1.77. Supernus Pharmaceuticals Inc. has a 12 month low of $9.51 and a 12 month high of $26.30.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.05. The business had revenue of $50.40 million for the quarter, compared to analyst estimates of $49.67 million. Supernus Pharmaceuticals had a return on equity of 20.99% and a net margin of 14.94%. The company’s quarterly revenue was up 43.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.03 earnings per share. On average, analysts expect that Supernus Pharmaceuticals Inc. will post $0.68 earnings per share for the current fiscal year.

A number of equities research analysts recently issued reports on SUPN shares. Jefferies Group reissued a “buy” rating and issued a $28.00 target price (up previously from $23.00) on shares of Supernus Pharmaceuticals in a research report on Thursday, August 4th. Zacks Investment Research raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a research report on Wednesday, July 6th. Northland Securities lowered Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 target price on the stock. in a research report on Monday, July 18th. Finally, Piper Jaffray Cos. lowered Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 target price on the stock. in a research report on Monday, July 18th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $24.50.

In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 2,000 shares of the firm’s stock in a transaction on Friday, September 16th. The stock was sold at an average price of $25.00, for a total value of $50,000.00. Following the completion of the sale, the chief financial officer now directly owns 3,616 shares of the company’s stock, valued at $90,400. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 6.10% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).

5 Day Chart for NASDAQ:SUPN

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.